<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573183</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-CTN-0031</org_study_id>
    <secondary_id>U10DA013714</secondary_id>
    <nct_id>NCT00573183</nct_id>
  </id_info>
  <brief_title>Stimulant Abuser Groups to Engage in 12-Step</brief_title>
  <acronym>STAGE-12</acronym>
  <official_title>Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combined group and individual 12-Step
      facilitative (TSF) intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12),
      improves substance -related outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is to evaluate the degree to which a combined group and individual 12-Step
      facilitative (TSF) intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12),
      improves substance -related outcomes compared to treatment as usual (TAU) without STAGE-12
      among stimulant abusers. The primary objective is to evaluate reduction in percent of days of
      stimulant use as measured by self-report. Secondary objectives include evaluating reduction
      in percent days of use of other substances, the degree to which STAGE-12 increases
      involvement in 12-step activities and attendance at 12-step meetings, and the extent to which
      such 12 -step involvement and meeting attendance mediate substance use outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of Stimulant Use</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of use of stimulant drugs within 30-day blocks across a 6-month post-baseline period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attendance at 12-step Meetings</measure>
    <time_frame>6 months</time_frame>
    <description>Days of attendance at 12-step meetings within 30-day blocks across a 6-month post-baseline period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">471</enrollment>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>STAGE-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>STAGE-12</intervention_name>
    <description>The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.</description>
    <arm_group_label>STAGE-12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  seeking outpatient treatment for stimulant abuse or dependence

          -  current diagnosis of stimulant abuse or dependence

          -  willing to participate in the protocol

        Exclusion Criteria:

          -  not sufficiently medically or psychiatrically stable

          -  pending legal action that would inhibit their participation in the study

          -  in need of detoxification from opiates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Donovan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Daley, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Community Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hina Mauka Kaneohe Rehabilitation Services</name>
      <address>
        <city>Kaneohe</city>
        <state>Hawaii</state>
        <zip>96744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryhaven, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Family Treatment Services</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChangePoint, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Medicine Services (WPIC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorchester Alcohol and Drug Commission</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Recovery Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Manor, Inc.</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recovery Centers of King County</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.drugabuse.gov/about-nida/organization/cctn/ctn/research-studies/stimulant-abuser-groups-to-engage-in-12-step-stage-12-evaluation-combined-i</url>
    <description>Link to description of the STAGE-12 protocol on the NIDA Clinical Trials Network web site</description>
  </link>
  <results_reference>
    <citation>Donovan DM, Daley DC, Brigham GS, Hodgkins CC, Perl HI, Garrett SB, Doyle SR, Floyd AS, Knox PC, Botero C, Kelly TM, Killeen TK, Hayes C, Kau'i Baumhofer N, Seamans C, Zammarelli L. Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network. J Subst Abuse Treat. 2013 Jan;44(1):103-14. doi: 10.1016/j.jsat.2012.04.004. Epub 2012 May 31. Erratum in: J Subst Abuse Treat. 2015 Feb;49:71. Kau'ibaumhofer, Nicole [corrected to Kau'i Baumhofer, Nicole].</citation>
    <PMID>22657748</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <results_first_submitted>June 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2014</results_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Dennis Donovan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cocaine, methamphetamine, amphetamine, other stimulant drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>STAGE-12</title>
          <description>Received 3 individual and 5 group sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program.</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual</title>
          <description>Received standard care provided in intensive outpatient drug treatment program</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>STAGE-12</title>
          <description>Received 3 individual and 5 group sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program.</description>
        </group>
        <group group_id="B2">
          <title>Treatment as Usual</title>
          <description>Received standard care provided in intensive outpatient drug treatment program</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="234"/>
            <count group_id="B2" value="237"/>
            <count group_id="B3" value="471"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="471"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.24" spread="10.04"/>
                    <measurement group_id="B2" value="38.45" spread="9.40"/>
                    <measurement group_id="B3" value="38.35" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days of Stimulant Use</title>
        <description>Number of days of use of stimulant drugs within 30-day blocks across a 6-month post-baseline period</description>
        <time_frame>6 months</time_frame>
        <population>The original sample size was based on power analysis and took attrition into account. Of the 471 individuals randomized to treatment, 50 subjects (TAU, n=20, STAGE-12, n=30) did not have any post-baseline measures and were therefore eliminated from the statistical analysis of the primary outcome and some of the secondary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>Standard treatment as usual in intensive outpatient substance abuse treatment program</description>
          </group>
          <group group_id="O2">
            <title>STAGE-12</title>
            <description>Received 3 individual and 5 group sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Stimulant Use</title>
          <description>Number of days of use of stimulant drugs within 30-day blocks across a 6-month post-baseline period</description>
          <population>The original sample size was based on power analysis and took attrition into account. Of the 471 individuals randomized to treatment, 50 subjects (TAU, n=20, STAGE-12, n=30) did not have any post-baseline measures and were therefore eliminated from the statistical analysis of the primary outcome and some of the secondary outcomes.</population>
          <units>days of stimulant use</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="5.39"/>
                    <measurement group_id="O2" value="2.13" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixture model with a logistic part for assessing zero-inflation and a negative binomial part for the over-dispersed count data, with corresponding 95% confidence intervals (CIs) of the odds ratios for logistic part and incidence rate ratios for negative binomial part.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>95% confidence interval</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A covariate adjustment was used: average number of days of stimulant use within a 30-day window of assessment from 90 days pre-baseline to baseline.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.3404</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2019</ci_lower_limit>
            <ci_upper_limit>9.2842</ci_upper_limit>
            <estimate_desc>The STAGE-12 group represented the numerator and TAU represented the reference group/denominator</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.4373</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0131</ci_lower_limit>
            <ci_upper_limit>5.8637</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attendance at 12-step Meetings</title>
        <description>Days of attendance at 12-step meetings within 30-day blocks across a 6-month post-baseline period</description>
        <time_frame>6 months</time_frame>
        <population>The sample size was originally powered based on the primary outcome measure, not on the secondary 12-step measures.The analysis sample size was reduced due to missing values</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-12</title>
            <description>Received 3 individual and 5 group sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>Standard treatment as usual in intensive outpatient substance abuse treatment program</description>
          </group>
        </group_list>
        <measure>
          <title>Attendance at 12-step Meetings</title>
          <description>Days of attendance at 12-step meetings within 30-day blocks across a 6-month post-baseline period</description>
          <population>The sample size was originally powered based on the primary outcome measure, not on the secondary 12-step measures.The analysis sample size was reduced due to missing values</population>
          <units>days of attending 12-step meetings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.01" spread="9.73"/>
                    <measurement group_id="O2" value="10.52" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome measure: Number of days of self-reported Self-Help meeting attendance by the Substance Use Calendar (SUC) within a 30-day window of assessment at mid-treatment, end-of-treatment, first, second, third and last follow-ups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Statistical Model - zero-inflated negative binomial random-effects regression</p_value_desc>
            <method>Zero-inflated negative binomial random-e</method>
            <method_desc>Statistical Model - zero-inflated negative binomial random-effects regression adjusted for average number of days of pre-baseline attendance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>STAGE-12</title>
          <description>Received 3 individual and 5 group sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions.</description>
        </group>
        <group group_id="E2">
          <title>Treatment as Usual</title>
          <description>Standard treatment as usual in intensive outpatient substance abuse treatment program</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>gateroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pelvic inflamatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>stitch abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>partial seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>depression suicidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>hallucination, auditory</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>hallucination, mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>homicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>suicide attempt</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="234"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="234"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="234"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="234"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dennis Donovan</name_or_title>
      <organization>Univerity of Washington Alcohol &amp; Drug Abuse Institute</organization>
      <phone>206-543-0937</phone>
      <email>ddonovan@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

